SALINE-FILLED BREAST IMPLANT AVAILABILITY SHOULD BE LIMITED
This article was originally published in The Gray Sheet
Executive SummarySALINE-FILLED BREAST IMPLANT AVAILABILITY SHOULD BE LIMITED to controlled trials, Public Citizen's Health Research Group says in an Aug. 4 petition to FDA. "Pending a final decision by the FDA regarding whether they are sufficiently safe and effective," HRG argues, "any further use of the devices should be limited" to a three-stage clinical protocol similar to that currently in place for silicone gel-filled breast implants.
You may also be interested in...
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.